Research notes from Dr. Miyamoto

We are pleased to let you hear Dr. Sayuri Myiamoto present her preliminary work, listen to the video. There is a lot more to learn, and her lab is working on the next steps. She is publishing her novel data, we will let you know when the manuscript finishes and in the review process. A part of her work is testing ALS patients for the novel lipid markers they have identified. Although the lipid marker isn't specific for ALS, once ALS is diagnosed, it may be a prognostic marker.


We are hopeful that finding treatments that can modify (increase) this marker in a person the drugs would bring benefit to ALS patients, perhaps slowing disease progression.

11 views0 comments

Recent Posts

See All

San Francisco-based Verge Genomics has begun a phase 1 human trial for its ALS drug candidate, VRG50635, that was discovered by Artificial Intelligence, AI. This novel method of discovery may speed up

NDR is pleased to announce research support for Ghada Maged for an ALS biomarkers project. Ms. Maged is currently completing an M. Sc. degree in Master of Neuroscience at Alexandria University in Egyp